CORONA Remedies Q3 FY26: Revenue Up 15% to ₹342 Cr, PAT Grows 24%
CORONA Remedies reported Q3 FY26 revenue of ₹342 Cr, up 15% YoY, and PAT of ₹56 Cr, up 24% YoY. For 9M FY26, revenue reached ₹1,050 Cr (up 16%), and PAT was ₹154 Cr (up 31%). The company is the fastest-growing among top 30 Indian pharma firms, with an 18.9% growth in Q3 FY26. It expects mid-teen revenue growth and high-teen PAT growth going forward.
The announcement details significant financial performance improvements, strategic growth initiatives including new product launches and market expansion, and positive future guidance. These factors are likely to have a substantial impact on investor perception and the company's valuation.
The company reported strong year-on-year growth in revenue and profit after tax for both the quarter and the nine-month period. The financial performance exceeded guidance in some areas, and the company highlighted its outperformance compared to the broader Indian Pharmaceutical Market. Positive outlook and strategic initiatives also contribute to the sentiment.
CORONA Remedies Limited announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a 15% year-on-year increase in revenue for Q3 FY26, reaching ₹342 crore, compared to ₹298 crore in Q3 FY25. EBITDA for the quarter grew by 20% to ₹83 crore, with EBITDA margins improving by approximately 100 basis points to 24.3%. Adjusted profit after tax (PAT) for the quarter was ₹56 crore, a 24% rise from ₹45 crore in the same period last year.
For the nine-month period of FY26, revenue stood at ₹1,050 crore, marking a 16% growth over ₹903 crore in the corresponding period of FY25. EBITDA for the nine months increased by 25% to ₹231 crore, with EBITDA margins improving by 140 basis points to 22%. Adjusted PAT for the nine months grew by 31% to ₹154 crore, against ₹118 crore in the prior year.
The company highlighted its strong performance relative to the Indian Pharmaceutical Market (IPM), being the fastest-growing among the top 30 pharma companies in India for Q3 FY26, with an 18.9% growth compared to IPM's 9.6%. The company is focused on increasing market share in key therapy areas, particularly chronic and semi-chronic segments, and plans to launch new products and expand its portfolio through brand acquisitions and in-licensing. The EU GMP accreditation for its Gujarat facility opens up opportunities in five EAEU member countries.
Looking ahead, CORONA Remedies expects to continue growing its revenue in the mid-teen range and PAT at a high-teen range. The company is also strategically expanding its workforce, with 600 medical representatives added over the past three years, and is focusing on scaling its IVF portfolio and preparing for the launch of GLP-1 injectables. The company maintains a net cash surplus position and reinvests for growth.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.